TLR7 and skin cancer: Solid nanoemulsion containing a combination of imiquimod, a Toll-like receptor 7 (TLR7) agonist, and model peptide antigen SIINFEKL for the topical treatment of different types of precancerous skin lesions and skin cancer, as a new perspective to avoid invasive technique and enhance dermal antigen administration [21].